Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2008

View Archived Issues

Antiviral effects of rapamycin in mouse model of HIV infection

SRI-21950 active against vaccinia and cowpox viruses in mice

Lexicon presents early clinical results of LX-6171 at the AAN meeting

Proposed merger between Inflazyme and Z-Tech is terminated

Fusion construct targeting carcinoembryonic antigen cytotoxic in vitro

XIAP knockdown allows cancer cell apoptosis with TRAIL in resistant cells

New farnesoid X receptor agonist shows preclinical potential in dyslipidemia

FDA accepts Huya's IND-enabling nonclinical and clinical development plans for chidamide

E.U. approves new powerful antihypertensive MicardisPlus 80/25

Kythera commences second phase II ATX-101 trial for reduction of submental fat

Pfizer completes tender offer for shares of Encysive

Phase II trial shows safety and immunogenicity for Japanese encephalitis vaccine

SIGA advances ST-246 smallpox candidate development in Europe

Avapro obtains Japanese manufacturing and marketing approval

FDA grants fast track designation for RG-1068 in pancreatic imaging

FDA grants orphan drug designation for Zymenex's enzyme, Metazym

Insert initiates phase II clinical trial with lead drug candidate IT-101 for ovarian cancer

Novel antipsychotic YKP-1358 shows good safety and D2 receptor affinity in humans

MethylGene initiates phase I clinical trial for MGCD-265 in solid tumors

Novartis receives approval for Exjade in Japan

Ono and Dainippon Sumitomo discontinue limaprost in cervical spondylosis

Aldagen initiates treatment in phase III clinical trial of ALD-101 for cord blood transplants

New antiinflammatory agents reported in recent Nycomed patent

Novartis divulges novel S1P1 receptor agonists in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.